Publications by authors named "S Wiertlewski"
Purpose: The last updates to diagnostic criteria for multiple sclerosis (MS) included a diagnostic category of 'possible MS'. However, no recent data is available to assess how much this distinction helps predict MS after isolated optic neuritis (ON). This study aimed to assess the global risk of developing MS one year after a first ON episode, and the specific risk according to the initial diagnosis of isolated ON or ON with possible MS.
View Article and Find Full Text PDFIntroduction: Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis. Its diagnosis is difficult as there is no specific test for it. Because of its rarity, the management of NS has so far only been described in case series and short retrospective cohorts.
View Article and Find Full Text PDFArticle Synopsis
- * Conducted over eight years (2015-2023) using data from a French MS registry, researchers categorized relapses based on MRI results to better understand their impact.
- * Findings indicate that certain factors, like treatment type and fatigue, increase the likelihood of clinically defined relapses without MRI evidence, suggesting a need for revised monitoring and treatment strategies for MS patients.
Article Synopsis
- A pilot study investigated the gut and oral microbiota in multiple sclerosis (MS) patients and found significant bacterial alterations compared to healthy volunteers (HV).
- The analysis revealed decreased diversity and specific bacteria depletion in MS patients, along with enrichment of inflammation-associated bacteria and altered microbial pathways.
- A distinctive oral metabolite signature was identified in MS patients, which has high specificity for discriminating them from HV and patients with rheumatoid arthritis, suggesting the potential for future research on oral microbiota in autoimmune diseases.
Purpose: To compare the efficacy of treatment of optic neuritis (ON) with corticosteroids (CTC) alone, CTC+plasmapheresis (PLP), and CTC+intravenous immunoglobulin (IVIG).
Design: After an episode of ON, although visual recovery is usually good, some patients may have significant visual sequelae. While the efficacy of first-line CTC is now indisputable, there is no consensus on the nature of second-line treatment.